Cargando…

Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma

PURPOSE: Our purpose was to describe the long-term outcomes seen with the addition of concurrent weekly docetaxel to high-dose intensity modulated radiation (IMRT) to the prostate and androgen deprivation therapy in patients with high-risk nonmetastatic adenocarcinoma of the prostate. METHODS AND MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	McVorran, Shauna, Keane, Thomas, Marshall, David T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Scientific Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677196/ https://www.ncbi.nlm.nih.gov/pubmed/36420198 http://dx.doi.org/10.1016/j.adro.2022.100935

Ejemplares similares

Systemic Lupus Erythematosus Presenting with Massive Ascites: A Case of Pseudo-Pseudo Meigs Syndrome
por: McVorran, S., et al.
Publicado: (2016)

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy
por: Jackson, William C., et al.
Publicado: (2015)

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
por: Mellado, B, et al.
Publicado: (2009)

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer
por: Gadia, Rafael, et al.
Publicado: (2016)

Trends in Androgen Deprivation Use in Men With Intermediate-Risk Prostate Cancer Who Underwent Radiation Therapy
por: Agrawal, Vishesh, et al.
Publicado: (2022)

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003
por: Laughlin, Brady S., et al.
Publicado: (2022)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

The Long-Term Effect of Intensity Modulated Radiation Therapy for Prostate Cancer on Testosterone Levels
por: Horiguchi, Yutaka, et al.
Publicado: (2021)

Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer
por: Salami, Simpa S., et al.
Publicado: (2016)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Role of maximum androgen blockade in advanced prostate cancer
por: Ayyathurai, Rajinikanth, et al.
Publicado: (2009)

Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer
por: Thalgott, Mark, et al.
Publicado: (2014)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study
por: Gresswell, Steven, et al.
Publicado: (2016)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
por: Mirjolet, Céline, et al.
Publicado: (2017)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
por: D'Amico, Anthony V., et al.
Publicado: (2021)

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
por: Fujimura, Tetsuya, et al.
Publicado: (2018)

Predicting castration-resistant prostate cancer after combined androgen blockade
por: He, Miao, et al.
Publicado: (2017)

Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis
por: Parikh, Nainesh, et al.
Publicado: (2020)

Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma
por: Koong, Amanda J., et al.
Publicado: (2017)

Prolonged Remission of Prostate Cancer Presenting as Endobronchial Metastases Following Total Androgen Blockade: A Case Report and Literature Review
por: Freund, Robert S., et al.
Publicado: (2019)

Bowel and Bladder Reproducibility in Image Guided Radiation Therapy for Prostate Cancer: Results of a Patterns of Practice Survey
por: Rowe, Lindsay S., et al.
Publicado: (2022)

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
por: Lukka, H., et al.
Publicado: (2006)

Exceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancer
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19
por: Zaorsky, Nicholas G., et al.
Publicado: (2020)

Immediate Impact of an Intensive One-Week Laparoscopy Training Program on Laparoscopic Skills Among Postgraduate Urologists
por: Vlaovic, Peter D., et al.
Publicado: (2008)

Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer
por: Natesan, Divya, et al.
Publicado: (2021)

Sentinel lymph node imaging guided IMRT for prostate cancer: Individualized pelvic radiation therapy versus RTOG guidelines
por: Chen, Chien P., et al.
Publicado: (2015)

Comparison Between Dose-Escalated Intensity Modulated Radiation Therapy and 3-Dimensional Conformal Radiation Therapy for Salvage Radiation Therapy After Prostatectomy
por: Shimoyachi, Nana, et al.
Publicado: (2021)

Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
por: Diab, Osama, et al.
Publicado: (2019)

Clinical Outcomes of Combined Prostate- and Metastasis-Directed Radiation Therapy for the Treatment of De Novo Oligometastatic Prostate Cancer
por: Imber, Brandon S., et al.
Publicado: (2020)

Salvage Prostate Stereotactic Body Radiation Therapy After Definitive Cryoablation
por: Lischalk, Jonathan W., et al.
Publicado: (2021)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pst16337u7kqcqsahgh12l45oi